VanEck Biotech ETF BBH
251.01 USD -10.62 (-4.06%)
At closeNov 5, 2026, 4:00 PM EST
250.80 -0.21 -0.08%
After hours · Nov 5, 4:00 PM ET
251.01 Day range 263.74
179.90 52-week range 261.63
- YTD
- +32.63%
- 1 year
- +38.09%
- Market cap
- 538.03M
- EPS (ttm)
- 8.95
- P/E ratio
- 28.04
- YTD return
- +32.63%
- 1-year return
- +38.09%
- Volume
- 27.19K
- Avg volume
- 11.92K
- Open
- 263.74
- Previous close
- 261.63
- Day's range
- 251.01 – 263.74
- 52-week range
- 179.90 – 261.63
2Y +78.26 (+45.30%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 167.95
- 200-day average
- 169.82
About VanEck Biotech ETF
The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index includes common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
News
ETFs That You May Consider Amid a Strengthening Biotech Outlook 
Why Healthcare ETFs Are Hovering Around One-Year Highs 
Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy? 
Biotech ETF (BBH) Hits New 52-Week High 
BBH Capital Partners Private Equity Exits The Granite Group 
Better Biotechnology ETF: First Trust FBT vs. VanEck BBH 
Better Healthcare ETF: VanEck's Biotech-Focused BBH vs. State Street's XPH Targeting Pharma 
Fidelity Healthcare ETF (FHLC) vs. VanEck Biotech ETF (BBH): Which Fund Is the Better Buy? 
Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate 
Should You Invest in the VanEck Biotech ETF (BBH)?
Your note
Sign in to keep a note on BBH — it syncs with the Stock Master app.